Background: The expression of the inhibitor of apoptosis proteins (IAPs) family has not been fully investigated in colorectal carcinomas. This study investigated IAP expression in colorectal carcinomas and assessed their prognostic significance. Methods: Livin, XIAP, and SMAC/DIABLO expression was assessed by immunohistochemistry in 159 colorectal carcinomas. Correlations between protein expression and clinicopathological features were evaluated. The survival data analysis was estimated according to the Kaplan-Meier method. Results: Increased expression of IAPs in cancer tissues compared to surrounding nonneoplastic counterparts was observed in 67 cases (42.1%) for Livin, 50 cases (31.4%) for XIAP, and 68 cases (42.8%) for SMAC. A significant correlation was found between Livin expression and tumor differentiation, and SMAC expression and tumor location. The recurrence-free and overall survival of patients with low Livin expression were inferior to those of patients with high Livin expression (p = 0.054 and 0.095, respectively). High XIAP expression was significantly associated with shorter progression-free survival (p= 0.041). Conclusions: Our study demonstrated that altered expression of IAP family members, including Livin, XIAP, and SMAC, is frequent in colorectal carcinoma. This result suggests that high Livin expression and low XIAP expression may be a favorable prognostic implication related to patient survival.
Colorectal carcinoma (CRC) remains one of the leading causes of cancer mortality despite remarkable advances in cancer diag nostics and treatment. 1 Similar to other malignancies, deranged apoptotic cell death is one of the important mechanisms of car cinogenesis and tumor progression of CRC. 2 This process is me diated by a group of proteins called inhibitor of apoptosis pro teins (IAP), which have potential antiapoptotic functions by inhibiting caspase activities. 3, 4 Previous studies have suggested that IAP overexpression results in survival of neoplastic cells and therapeutic resistance to cytotoxic agents. 3 Overexpressed IAPs have been documented in a variety of solid tumors and cancer cell lines. 3 IAPs are characterized by the presence of one or more repeats of a highly conserved 70 amino acid domain, termed the bacu loviral IAP repeat (BIR). Livin is a novel member of the IAP family, originally identified in melanoma. 3 Recently, Livin ex pression has been found to be overexpressed in various cancers, including bladder cancer, lung cancer, acute lymphoblastic leu kemia, and neuroblastoma. 58 Livin is selectively expressed in the most common human neoplasms and appears to be involved in tumor cell resistance to chemotherapeutic agents. 4 Several in vitro and in vivo studies have demonstrated that downregulation of Livin expression increases the apoptotic rate, reduces tumor growth potential, and sensitizes tumor cells to chemotherapeu tic drugs. 9, 10 To date, little is known about Livin expression in CRC and its association with clinical implications. The aim of the present study was to investigate the expression of Livin along with its closely related IAP member, XIAP, and an endogenous antago nist of IAP proteins, SMAC/DIABLO, in a series of 159 CRC cases.
Inhibitors of Apoptosis Proteins Expression and Their Prognostic
Significance in Colorectal Carcinoma
MATERIALS AND METHODS

Patient selection and sample collection
Primary tumor samples were collected from 159 patients di agnosed with colorectal adenocarcinoma at Chonnam National University Hwasun Hospital. The patients had undergone a colectomy between April 2004 and December 2004. The cases were identified retrospectively from clinicopathological data. The availability of adequate tissue material and clinical follow up data were the only inclusion criteria. The following clinico pathological characteristics were evaluated for their relevance to protein expression or longterm survival: age (>60 yr vs ≤60 yr), gender, tumor size (>4.5 cm vs ≤4.5 cm), tumor location (proximal vs distal), tumor differentiation (high grade vs low grade), tumor extent (T1, T2 vs T3, T4), lymph node metasta sis, distant metastasis, and history of chemoradiation treatment after surgery. No patient received chemoradiation treatment preoperatively. The lowgrade group consisted of well and mod erately differentiated adenocarcinomas, whereas the highgrade group consisted of poorly differentiated adenocarcinomas, in cluding mucinous carcinomas. Tumor extent and staging was determined using the American Joint Committee on Cancer tumor, node and metastasis system. 11 The patient's progression free survival (PFS) and overall survival (OS) were calculated from the date of surgery. The survival endpoint was the date of last followup or progression and death. This study was approved by the Institutional Review Board of Chonnam National Uni versity Hospital.
Immunohistochemistry
Immunohistochemisty for Livin, XIAP, and SMAC/DIABLO was performed using formalinfixed, paraffinembedded tissue sections and the avidinbiotin complex method. Briefly, repre sentative paraffin blocks were cut consecutively at 4 µm thick ness, deparaffinized in xylene, and treated with 0.3% hydrogen peroxide in methanol for 20 minutes to block endogeneous per oxidase activity. Sections were subjected to pressurecooking for 7 minutes in 10 mM citrate phosphate buffer (pH 6.0) and then incubated with primary antibodies for 60 minutes at room temperature. Antibodies to Livin (1 :200, Active Motif, San Diego, CA, USA), XIAP (1:100, BD Biosciences, San Jose, CA USA), and SMAC/DIABLO (1:100, R&D Systems, Minneapo lis, MN, USA) were used. Antimouse immunoglobulin G (Sigma, St. Louis, MO, USA) labeled with biotin was used as a secondary antibody and was incubated for 7 minutes at 45˚C. Avidinbiotin peroxidase complex staining using diaminoben zidine (Sigma) as the chromogen was performed with a Strepta vidinHorseradish Peroxidase Detection system (Ventana, Bio tek Solutions, Tucson, AZ, USA). Negative controls were treat ed similarly with the exception of primary antibodies. Tissue from melanoma, esophageal cancer, and lung cancer samples were used as positive controls. Immunohistochemical staining was completed in duplicate for samples that did not agree. A high level of agreement was achieved using this procedure. As sessment for staining intensity was performed as follows: low, weak staining in cytoplasm and/or the nucleus compared to that of nontumoral epithelial cells; and high, readily appreciable or dark brown staining distinctly marking the tumor cell cyto plasm and/or nucleus. Immunohistochemical staining was re evaluated for cases showing disagreement between observers. Two pathologists reviewed the cases together and then reached an agreement for inconclusive samples. Tumor cell staining in tensity was evaluated in coded slides by two of the authors, and the evaluation was performed twice without any knowledge of the clinical details.
Statistical analyses
Statistical analyses were performed with the SPSS ver. 15.0 (SPSS Inc., Chicago, IL, USA). The relationship between pro tein expression and categorical variables was compared by the χ 2 test, or Fisher exact probability test, when appropriate. Sur vival curves were estimated using the KaplanMeier method. The distribution of survival was comparatively studied using the logrank test. Independent prognostic factors were deter mined using the Cox's proportional hazard model. The level of significance was set at p<0.05.
RESULTS
Clinicopathological findings
Clinicopathological findings from the 159 cases selected for this study were reviewed. The average age of onset of the pa tients was 61.7 years (range, 21 to 85 years); the subjects in cluded 95 males and 64 females. The patients were followed for an average time of 47.8 months (range, 1 to 81 months) to de termine clinical outcomes. Among the 159 resected cases, the primary tumor size varied from ≤4.5 cm in 76 cases to >4.5 cm in 83 cases. The locations of the cancers were the proximal colon from the cecum to the splenic flexure in 35 cases and the distal colon from the splenic flexure to the rectum in 124 cases. Twentyone of 159 tumors showed high grade differentiation. The tumor extent was limited (T1 or T2) in 27 cases and ad vanced (T3 or T4) in 132 cases. Tumor metastasis to the lymph nodes was observed in 78 of 159 cases, and tumor metastasis to distant organs was observed in 18 cases ( Table 1) .
Expression of IAPs and correlation with clinicopathological factors
The intensity of IAP expression in CRCs was measured by immunohistochemistry. Livin, XIAP, and SMAC positive im munoreactivity was observed almost exclusively in the cyto plasm. In nontumoral mucosa cells, Livin, XIAP, and SMAC exhibited mild cytoplasmic localization (Fig. 1A) . However, they were significantly overexpressed in cancer tissues compared to nonneoplastic counterparts (Fig. 1D ). Cases in which protein expression in tumor tissues was comparable to or weaker than surrounding nontumoral tissues were categorized into a low ex pression group (Figs. 1B, C, 2A, C), and cases with higher pro tein expression in tumor tissues than in the surrounding coun terparts were categorized into a high expression group (Fig. 2B,  D) . High Livin, XIAP, and SMAC expression was found in 67 tumors (42.1%) of 159 samples and in 50 (31.4%) and 68 (42.8%) of 159 CRC cases, respectively (Table 2) .
IAP immunoreactivity and clinicopathological characteristics
The association between IAP protein expression and clinico pathological features was also examined in patients with CRC. A significant correlation was found between high Livin expres sion and lowgrade tumor differentiation (p=0.031). Livin ex pression tended to be high in tumors located distally, but the difference was not statistically significant (p=0.066) ( Table 2 ). Low SMAC expression was highly associated with tumors lo cated distally (p=0.007). XIAP expression did not show any significant correlation with the clinicopathological factors.
Analysis for recurrence-free survival (RFS) and OS
KaplanMeier curves were plotted using the staining results to determine the prognostic importance of Livin, XIAP, and SMAC expression in colorectal cancer. Livinhigh patients sur vived significantly longer than Livinlow patients in terms of both RFS (median survival period, 62.5 months vs 54.1 months, respectively) and OS (median survival period, 64.3 months vs 56.4 months, respectively), although survival benefits showed a statistically borderline significance (p=0.054 and p=0.095, re spectively) (Figs. 3A, 4) . XIAPlow patients demonstrated a significantly longer PFS than XIAPhigh patients (median survi val period, 62.1 months vs 49.9 months, respectively, p=0.041) (Fig. 3B) , although no significant difference in OS was observed between the XIAPlow group and the XIAPhigh group (me dian survival period, 61.7 months vs 56.4 months, respectively, p=0.364). In contrast, no difference was observed in the PFS and OS rates between patients with high or low SMAC expres sion (p=0.506 and p=0.775, for PFS and OS, respectively). In univariate survival analyses, the following clinicopathological factors had a statistically significant affect on PFS and OS in pa tients with CRC: tumor extent, lymph node metastasis, distant metastasis, tumor differentiation, and tumor size (p<0.05 for all and data not shown). Tables 3 and 4 show the results of the multivariate analysis using the Cox proportional hazards model for PFS and OS. The covariates included in the model were IAP expression, age, gen der, stage, tumor differentiation, tumor location, tumor size, and chemoradiation treatment. The factors were simplified into two groups for better statistical discrimination in the Cox re gression analysis. The results revealed that tumor size and stage were independent prognostic factors for both RFS and OS. Ad ditionally, high XIAP expression had a statistically significant borderline influence on progression and highgrade tumor dif ferentiation on death.
DISCUSSION
Eight IAPs have been identified in human cells to date, in cluding NAIP, cIAP1 (MIHB, HIAP2), cIAP2 (HIAP1, MIHC, API2), XIAP (hILP, MIHA, ILP1), survivin, BRUCE (apollon), ILP2, and Livin (MLIAP, KIAP). 3 Increasing evi dence has suggested that the IAP family of proteins is essential for regulating apoptosis and nuclear factorκB (NFκB) signal transduction. 3 Livin is a recently identified member of the IAP family and has been recognized as a potential modulator of apoptosis and survival in cancer. 3 Livin is not detectable in most adult tissues except the heart, lung, spleen, ovary, testes, and placenta but is present in transformed cells and in a variety of cancers. 12, 13 Livin antagonizes apoptotic activity by inhibiting caspases3, 7, and 9. 12 Wang et al. 10 reported that Livin gene downregulation using siRNA led to apoptosis and chemosensitivity enhancement in tumor cells, whereas other researchers have demonstrated that Livin overexpression renders malignant cells resistant to chemo therapy. 9 Livin increases selectively in gastric cancer tissues com pared with surrounding nontumoral tissues. 14 Wang et al. 15 show ed that knockdown of Livin expression by siRNA rendered tu mor cells from a colorectal cell line sensitive to chemotherapeu tic agents. Nevertheless, no reports are available on the relation ship between Livin expression and survival outcomes in patients with CRC in the English literature. The present study showed a strong trend for better PFS and OS in patients with high Liv in expression than in patients with low Livin expression. Addi tionally, high Livin expression correlated with lowgrade tumor differentiation. This result appeared to be contrary to the gener al understanding of IAPs, as Livin is a member of the IAP fam ily and is supposed to be associated with a poor prognosis by prolonging cancer cell survival. However, the prognostic impli cation of Livin expression varied according to tumor type. Livin expression level is unrelated to patient survival in nasopharyn geal carcinoma 16 and hepatocellular carcinoma. 17 In patients with neuroblastoma, high Livin expression decreases survival only when combined with amplified MYCN, whereas Livin ex pression alone has no effect on survival. 8 In contrast, a favorable prognosis was reported in patients with Livinpositive malig nant pleural mesotheliomas 18 and similarly in childhood acute lymphoblastic leukemia. 5 The Livin gene encodes two splicing variants called Livinα and Livinβ. 13, 19 These two isoforms play different roles in the antiapoptotic capacity of tumor cells and may represent a regu latory balance between apoptosis and its counterpart. 4 Clinical ly, Livinα is getting more attention because it is more closely related to tumor behavior than Livinβ. Increased Livinα ex pression is related to the proportion of bladder tumors with a high risk of relapse, possibly by regulating the G1S cell cycle transition. 7, 20 In contrast, some researchers have reported that Livinα displays a paradoxical proapoptotic effect in response to certain stimuli depending on subcellular localization and mu tation at the cleavage site, which eliminates this proapoptotic effect of Livinα. 13, 21 Although Ashhab et al. 13 showed high lev els of both α and βisoforms in colon carcinoma cell lines, dif ferences in the distribution of Livin according to its splicing va riants remain to be clarified.
XIAP is unique in that it directly binds and inhibits activated caspases. 22 For example, XIAP sequestrates caspase9 through its BIR3 domain and suppresses caspase3 and caspase7 via its BIR2 domain with its Nterminal linker. 22 In addition, XIAP promotes NFκB activation by enhancing NFκB translocation from the cytoplasm into the nucleus. 23 Although Endo et al. 24 reported that XIAP mRNA expres sion is not different between normal and cancerous colorectal tissues, we observed higher XIAP expression in cancerous tis sues than that in surrounding normal tissues by immunohisto chemistry. Increased XIAP expression has been reported in a variety of human tumors as well, including esophageal carcino ma, clear cell renal carcinoma, ovarian carcinoma, lymphoma, and pancreatic cancer. 25 We correlated low levels of XIAP ex pression with a favorable PFS in our CRC series. A previous re port showed that a XIAPhigh group had significantly shortened PFS and OS in CRC. 26 Shi et al. 25 and Augello et al. 17 In cells expressing Livin, the ability of IAPs to inhibit cell death is reversed by SMAC coexpression or adding SMAC pep tides. 27 Livin has very highaffinity for SMAC but is significant ly inferior to XIAP in terms of caspase inhibition. It has been proposed that the inhibitory effect of Livin on caspase3 and caspase9 is minor, whereas the antiapoptotic effect of Livin could be ascribed to its antagonizing the XIAPSMAC interac tion rather than direct inhibition. 28 Because SMAC has a pro apoptotic effect, its expression should be considered a favorable prognostic marker in malignancies. Unfortunately, only a lim ited number of studies are available to date. Only one study has correlated SMAC expression with prognosis in patients with CRC. Endo et al. 29 proposed that the decrease in SMAC/DIAB LO expression is an independent factor determining a poorer prognosis of patients with CRC. In the present study, SMAC expression was correlated with proximal tumor location but did not show any significant survival difference according to expres sion level.
It is presumed that most IAP members would exert a similar influence on the clinical behavior of malignant tumors, consid ering the significant homology among IAP genes. However, the current results imply that there could be different biological roles for each IAP member according to tumor type. Although both Livin and XIAP presumably antagonize apoptotic activi ties within tumor cells, their effects on survival were opposite; high Livin expression was associated with a better prognosis, whereas high XIAP expression was associated with a worse pro gnosis. This observation suggests that Livin and XIAP may have additional molecular functions in addition to their apparent roles in apoptotic cascades in terms of biological balance within cells with both anti and proapoptotic consequences. 21 How altered IAP expression affects tumor progression remains to be clari fied. For a thorough understanding of the role of Livin in carci nogenesis, future investigations are needed to investigate the expression and subcellular localization of the protein and the re lationship between the Livinα and β isoforms.
In conclusion, our results demonstrated frequent alterations in the expression of IAP family members in a large series of CRC. The IAP expression profiles suggested that Livin and XIAP may play a substantial role as effective prognostic markers in CRC. Moreover, because of the preferential expression of Livin and XIAP in CRC tissues rather than in nontumoral tissues, these data suggest that targeting the pathways encompassing Livin and XIAP may be useful in a group of selective patients with altered gene expression.
